EXERT

EXERT

What is the EXERT Study? EXERT is a national, 18-month long, clinical trial to test whether physical exercise can slow the progression of early Alzheimer’s disease related memory problems or mild cognitive impairment in older adults. EXERT is taking place at 15...
CREAD 2

CREAD 2

What is the CREAD 2? A Study of Crenezumab Versus Placebo to Evaluate the Efficacy and Safety in Participants With Prodromal to Mild Alzheimer’s Disease (AD). This randomized, double-blind, placebo-controlled, parallel-group study will evaluate the efficacy and...
The Generation Program

The Generation Program

What is the Generation? The Generation Program is made up of two clinical trials: Generation Study 1 and Generation Study 2. Each trial will last for 5 – 8 years and will be investigating treatment that may be able to prevent the onset of Alzheimer’s. We’ll have many...
ADNI3

ADNI3

What is the ADNI3? For the last 12 years the Alzheimer’s Disease Neuroimaging Initiative has enrolled more than 800 patients and lead to significant advances in our understanding of Alzheimer’s Disease.  Now in its 3rd iteration, ADNI3 will advance our...
NILO-PD

NILO-PD

What is the NILO-PD? The Parkinson Study Group (PSG), under the direction of Tanya Simuni, MD (Northwestern University) is conducting a multi-center, randomized, double-blind, placebo-controlled study of nilotinib in individuals with Parkinson’s disease (PD). The...
Elko Washoe Winnemucca/Humboldt Clark Nye Lincoln White Pine Esmeralda Eureka Lander Pershing Churchill Storey Carson City Douglas Lyon Mineral